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Dear Sir,
Monoamine oxidase inhibitors (MAOIs) are effective
second-line treatment options for depression [1, 2]. A recent
study showed that tranylcypromine (TCP), a nonselective
and irreversible MAOI, remains commonly used in standard
psychiatric clinics [3]. The risk of hypertensive crisis due to
drug−food interactions when MAOIs are prescribed is
widely known. Less well appreciated is the fact that MAOIs
can cause addiction and that a particular patient population
may be at high risk. Here we present a case of TCP
dependence that brings together all signs and symptoms so
far described after TCP withdrawal, including delirium,
thrombocytopenia, insomnia, and mild liver damage.
Case
A 30-year-old woman diagnosed with major depressive
disorder and borderline personality disorder and with past
history of alcohol, marihuana, amphetamine, and cocaine
abuse, presented to the emergency room. For the preceding
1−2 years, she had been treated with TCP and titrated to
60 mg a day, along with chlorpromazine 350 mg at night
for “sleep.” Two months after the initiation of TCP, she
steadily increased her dose to 170 mg a day. In order to
maintain her TCP intake, the patient visited multiple
physicians in search for prescriptions. Three days prior to
admission, she ran out of TCP and gradually became agitated,
irritable, and paranoid. When she presented to the emergency
room, she was confused, unable to recognize her mother, and
oriented to person only. She was described as responding to
internal stimuli and laughing inappropriately. On physical
examination, she had a mild tachycardia, a severe tremor, and
extensive bruising involving upper and lower extremities.
Laboratory evaluation revealed a thrombocytopenia of
72,000/µl.
On further inpatient evaluation, her cognitive status
improved. By the second day, her platelets had decreased
to 55,000/µl, and on the third day, these cells dropped further
to 25,000/µl. During her third day of hospitalization, her
partial thromboplastin time (PTT) extended to 40.9 s and her
liver function tests showed an aspartate transaminase (AST)
of 106 IU/l. A liver ultrasound revealed fatty-acid infiltrates.
On day 6, her platelets returned to normal limits. Nine days
after admission, the patient was able to sleep 6 h without any
medication, and her tremor was completely resolved.
Discussion
This abrupt change in behavior and cognition coincides
with previously reported cases of delirium after acute
withdrawal from TCP [4–6]. It has been proposed that
delirium and paranoia could result from acute removal of
the sympathomimetic component of MAOIs on presynaptic
receptors [7]. Under normal conditions, this presynaptic
effect aims to diminish the release of catecholamines. It
is likely that when MAOIs are suddenly stopped,
norepinephrine and dopamine acutely increase in the
synapse, rendering patients susceptible to psychosis and
delirium [6, 7].
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Thrombocytopenia has also been previously described
after a sudden removal of TCP [4, 5, 8]. Even though the
reason for the thrombocytopenia in unclear, this has been
explained as a sympathomimetic effect secondary to TCP
withdrawal that results in spleen venous pooling and also as
a consequence of the long-term inhibition of MAO in
platelets which, in turn, may lead to a reduced life span of
these cells [9].
The AST increase, PPT extension, as well as the fatty-acid
infiltrate could have originated from MAOI abuse [4, 10].
This possibility is further supported by the AST and PTT
normalization after being off TCP for several consecutive
days. On the other hand, insomnia could be associated to a
rebound from rapid eye movement sleep suppression, as it
has been previously observed when MAOIs are abruptly
stopped [11].
The combination of a past history of substance abuse
and a diagnosis of either borderline or histrionic personality
disorder seems to render patients at higher risk of
developing MAOI dependence [11–17], perhaps because
these medications are either structurally similar to amphet-
amines [6, 17] or are, like selegiline, metabolized into
excitatory compounds [18].
Clinicians are exhorted to ponder the addictive potential
of MAOIs when prescribing these drugs.
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